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Abstract
Background: Hypoalbuminemia has been shown to be associated with increased mortality. We reported a mass
screening in 1990 of X town in Japan, which demonstrated a high prevalence of hepatitis C virus (HCV) infection.
This follow-up study determined, through a period of 12 years, whether serum albumin levels impact on the life
prognosis of the residents of X town.
Results: Of the 509 subjects, 69 had died and 55 had moved to other regions by 2002. Therefore, we analyzed 454
people for whom we could confirm life and death between 1990 and 2002. Albumin levels were assigned to two
groups, low (<4.0 g/L, group A) and normal (≥4.0 g/L, group B). Of the 454 subjects analyzed, 25 were in group A
and 429 in group B and the mortality was 68.0% (17/25 cases, P < 0.00001 vs. group B) and 12.1% (52/429),
respectively. Mortality from hepatocellular carcinoma (HCC) was 66.7% in group A (6/9 cases, P = 0.01 vs. group B)
and 15.8% (3/19) in group B. According to multivariate analysis, five factors - 50 years or older, low albumin level
(<4.0 g/L), abnormal AST level, history of smoking, and absence of alcohol consumption - were associated with
death. The adjusted odds ratios for these five factors were 20.65, 10.79, 2.58, 2.24 and 2.08, respectively, and each
was statistically significant.
Conclusions: We show that the serum albumin level is an independent risk factor for mortality from all causes in
the residents of X town and an important prognostic indicator. Improvement of hypoalbuminaemia should be
considered for improvement of prognosis.
Background
Hypoalbuminemia can be caused by various conditions,
including nephrotic syndrome [1,2], heart failure [3],
liver disease [4,5] and malnutrition [6]. Most cases of
hypoalbuminemia among hospitalized patients are
caused by acute and chronic inflammatory responses
[7]. Moreover, a strong association has been reported
between the serum albumin level and mortality [8]. The
serum albumin level is an independent risk factor for
all-cause mortality in older persons and an important
prognostic indicator [9].
From 1990, we have continued carrying out health
screenings of the residents of X town (adult population:
7,389) in northern Kyushu, Japan, where the prevalence
of hepatitis C virus (HCV) infection is the highest in the
country and the mortality from liver cancer is about
three times the national average [10-23]. The positive
rates of antibodies to HCV (anti-HCV), HCV RNA and
hepatitis B surface antigen (HBsAg) were, respectively,
23.6%, 17.9%, and 2.6% in 1990 [15]. We demonstrated
extrahepatic manifestations as well as the natural course
and carcinogenesis of HCV-infected persons in X town.
There has been little discussion about hypoalbumine-
mia and mortality over the long term in residents of the
area. In this study, we determined whether serum albu-
min levels impact on the life prognosis of the residents
of X town after a follow-up period of 12 years.
Methods
Subjects
In 1990, 10% (739 people) of the 7,389 inhabitants were
selected randomly and, as a result, 509 subjects partici-
pated in the study for examination of liver diseases
accompanying HCV or hepatitis B virus (HBV) infec-
tions [15]. We studied 509 consecutive residents
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died and 55 had moved to other regions by May 31,
2002. Therefore, 385 of the original inhabitants investi-
g a t e di n1 9 9 0c o n t i n u e dt or e s i d ei nXt o w ni nM a y
2002. Consequently, 454 residents, whose life and death
could be confirmed between 1990 and 2002, were stu-
died. The albumin levels were categorized into two
g r o u p s ,l o w( < 4 . 0g / L ,g r o u pA )a n dn o r m a l( ≥4.0 g/L,
group B) and there were 25 subjects in group A and
429 in group B.
Serological assays
In 1990, sera were provided by the 454 subjects for the
following serological assays: albumin, serum aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT). Sera were also examined for the presence or
absence of markers of HCV and HBV infection. Anti-
HCV was measured by a chemiluminescent enzyme
immunoassay (CLEIA) kit (Lumipulse II HCV, Fujirebio
Inc., Tokyo, Japan). HCV RNA was detected in the sera
using the Amplicor HCV test (Nippon Roche, Tokyo,
Japan). HBsAg was assayed by a chemiluminescent
immunoassay (CLIA) kit (Architect™, HBsAg QT, Daina-
bot Co. Ltd., Tokyo, Japan). Ultrasonographic examina-
tion of subjects with abnormalities in their liver function
tests and who were positive for anti-HCV or HBsAg was
performed in order to investigate the shape of the liver
and lesions occupying the hepatic space.
Physical examination
Obesity was defined as a body mass index (BMI) ≥ 25
kg/m
2 or greater. We also took a history of liver dis-
eases, smoking, and alcohol consumption. We compared
these factors between group A and group B. The total
intake of alcohol was estimated on the basis of informa-
tion about the consumption of beer, wine, whisky,
Japanese sake, and shochu. In addition, the cumulative
ethanol consumption up to 1990, expressed in kilo-
grams, was calculated approximately by converting the
alcohol intake in a serving of each type of alcoholic bev-
erage into grams.
Analysis of cause of death of the 69 individuals who had
died by 2002
Of the 509 inhabitants examined in 1990, 69 (34 men
and 35 women; mean age at death, 76.6 years) had died
by 2002. We compared the causes of death in group A
and group B.
Statistical analysis
All data are expressed as mean ± standard error. Differ-
ences between the two groups were analyzed using the
Mann-Whitney U test, Wilcoxon’s test, and the Fisher’s
exact test. Differences were judged significant for p <
0.05 (two-tailed). Adjusted odds ratios were calculated
using logistic regression analysis. All statistical analyses
were conducted using JMP Version 6 (SAS Institute,
Cary, NC, USA). The level of statistical significance was
defined as 0.05. Survival analysis was carried out using
the Kaplan-Meier method.
Results
Risk factors by univariate analysis
T h ed e t a i l so ft h e4 5 4s u b j ects studied are shown in
Table 1. We compared the characteristics of 25 subjects
whose serum albumin was <4.0 g/L (group A) and 429
subjects whose serum albumin was ≥4.0 g/L (group B).
The mean age in group A was 68.8 ± 14.5 years and
there were 16 men and nine women. The mean age in
group B was 51.9 ± 15.9 years and there were 180 men
and 249 women. Being male (P < 0.05), elderly (P <
0.0001), having a history of liver diseases (P < 0.01), his-
tory of smoking (P < 0.05), abnormal AST level (P <
0.01), being positive for anti-HCV (P = 0.0001), positive
for HCV RNA (P < 0.001), and occurrence of death (P <
0.00001) were significantly more common in group A
than in group B (Table 1). Mortality was 68.0% in group
A (17/25 cases, P < 0.00001 vs. group B) and 12.1% (52/
429) in group B, as shown in Table 1 and Figure 1. No
significant differences were observed between the two
groups regarding BMI, alcohol consumption, ALT level,
and positive rate of HBsAg.
Individuals were stratified according to cumulative
ethanol consumption by 1990: non-drinkers (227,
50.0%), <10 kilogram (62, 13.7%), 10-50 kilogram (37,
8.1%), 50-100 kilogram (21, 4.6%), and ≥100 kilogram
(107, 23.6%).
Table 1 Characteristics of subjects with low and normal
albumin levels
Group A Group B P value
Alb < 4.0 g/L Alb ≥ 4.0 g/L
n = 25 n = 429
Age (mean ± SD), years 68.8 ± 14.5 51.9 ± 15.9 <0.0001
Sex (male/female) 16/9 180/249 <0.05
BMI ≥ 25 4 (16.0%) 54 (12.6%) NS
History of liver diseases (yes) 15 (60.0%) 143 (33.3%) <0.01
Alcohol consumption (yes) 13 (52.0%) 214 (49.9%) NS
History of smoking (yes) 13 (52.0%) 139 (32.4%) <0.05
AST (IU/L) (mean ± SD) 47.0 ± 45.8 23.6 ± 14.7 <0.01
ALT (IU/L) (mean ± SD) 44.0 ± 71.2 22.8 ± 21.4 NS
Anti-HCV, positive 14 (56.0%) 96 (22.4%) 0.0001
HCV RNA, positive 11 (44.0%) 67 (15.6%) <0.001
HBsAg, positive 1 (4.0%) 9 (2.1%) NS
Death by 2002 17 (68.0%) 52 (12.1%) <0.00001
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The numbers of deaths from malignant tumor were 9
(52.9%) in group A and 19 (36.5%) in group B. These
fatal malignant tumors were hepatocellular carcinoma
(HCC, six), gastric cancer (two) and prostate cancer
(one) in group A and lung cancer (six), colon cancer
(four), HCC (three), gastric cancer (two), esophageal
cancer (one), leukemia (one), malignant lymphoma
(one) and unknown (one) in group B. Mortality from
HCC was 66.7% (6/9 cases, P = 0.01 vs. group B) in
group A and 15.8% (3/19) in group B. No significant dif-
ferences were observed between these two groups in
terms of the numbers of death from malignant tumors
other than HCC.
No significant differences were observed between the
two groups for mortality from cerebrovascular disease,
cardiac disease, pneumonia, liver disease, diabetes melli-
tus, suicide, tuberculosis, a freak accident, feebleness of
age, and others.
Multivariate analysis
According to multivariate analysis, five factors - 50 years
or older, low albumin level (<4.0 g/L), abnormal AST
level, history of smoking, and absence of alcohol con-
sumption - were associated with death. The adjusted
odds ratios for these five factors were 20.65, 10.79, 2.58,
2.24 and 2.08, respectively, and each was statistically sig-
nificant (Table 3).
Cumulative ethanol consumption of <10 kilogram or
10-50 kilogram played an important role in survival.
The adjusted odds ratios compared to absence of alco-
hol consumption were 6.44 (95% confidence interval:
1.93-39.92), and 7.72 (95% confidence interval: 1.62-
138.46), respectively.
Discussion
Low serum albumin levels are an important predictor of
morbidity and mortality [8,9] and correlate with an
increased risk of morbidity and mortality in hospitalized
patients. However, there has been little discussion about
hypoalbuminemia and mortality of the residents of an
area with an exceptionally high prevalence of HCV
infection. In this study, we determined whether serum
albumin levels affect the life prognosis of the residents
of X town.
Our results indicate a strong association between
hypoalbuminemia and mortality in this hyperendemic
area of HCV infection in Japan. Residents with hypoal-
buminemia had a mortality of 68.0%; dramatically higher
than the rate of 12.1% among residents who had normal
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Figure 1 12-year cumulative survival from 1990 to 2002
according to serum albumin concentration. Mortality of group A
(albumin < 4.0 g/L) and group B (albumin ≥ 4.0 g/L) was 68.0% (17/
25 cases, P < 0.00001 vs. group B) and 12.1% (52/429), respectively.
Table 2 Causes of death of subjects with low and normal
albumin levels
Group A Group B P value
Alb <
4.0 g/L
Alb ≥ 4.0
g/L
n=1 7 n=5 2
Malignant tumor HCC 6 66.7% 3 15.8% 0.01
gastric cancer 2 22.2% 2 10.5% NS
prostate cancer 1 11.1% 0 0.0% NS
lung cancer 0 0.0% 6 31.6% NS
colon cancer 0 0.0% 4 21.1% NS
esophageal cancer 0 0.0% 1 5.3% NS
leukemia 0 0.0% 1 5.3% NS
malignant lymphoma 0 0.0% 1 5.3% NS
unknown 0 0.0% 1 5.3% NS
total 9 52.9% 19 36.5% NS
Cerebrovascular disease 0 0.0% 10 19.2% NS
Cardiac disease 3 17.6% 6 11.5% NS
Pneumonia 3 17.6% 6 11.5% NS
Liver disease 1 5.9% 3 5.8% NS
Diabetes mellitus 0 0.0% 2 3.8% NS
Suicide 0 0.0% 2 3.8% NS
Tuberculosis 0 0.0% 1 1.9% NS
Freak accident 1 5.9% 1 1.9% NS
Feebleness of age 0 0.0% 1 1.9% NS
Other 0 0.0% 1 1.9% NS
HCC, hepatocellular carcinoma
Table 3 Results of multivariate analysis
Adjusted odds ratio P value
(95% confidence
interval)
50 years or older 20.65 7.08 - 88.71 <0.0001
Albumin < 4.0 g/L 10.79 4.02 - 32.75 <0.0001
Abnormal AST level (≥40 IU/L) 2.58 1.14 - 5.79 <0.05
History of smoking (yes) 2.24 1.08 - 4.65 <0.05
Non-alcohol consumption 2.08 1.03 - 4.36 <0.05
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tion and ALT value were associated with deaths due to
HCC or liver cirrhosis in this X town [17]. We also
showed that hypoalbuminemia was prognostic factor
about all-cause mortality.
It is estimated that ~170 million people worldwide are
infected with HCV [24], some two million (1%) of
whom reside in Japan [25]. HCV leads to serious conse-
quences such as liver cirrhosis and HCC. Of the HCC
cases in Japan, around 16% are caused by hepatitis B
virus (HBV) infection and around 80% by HCV infec-
tion. The increase in the number of HCC patients due
to HCV contributes to the increase in total deaths in
Japan from HCC. This trend is expected to continue
until 2015 [25].
Albumin, produced only by the liver, is the major pro-
tein that circulates in the blood. Albumin consists of
585 amino acids, has a molecular weight of approxi-
mately 69 kDa and is the most abundant plasma protein,
although 60% of the total albumin pool is in the intersti-
tial space [26]. Albumin is essential for maintaining the
oncotic pressure in the vascular system. A decrease in
oncotic pressure due to a low albumin level allows fluid
to leak from the interstitial spaces into the peritoneal
cavity, producing ascites. Albumin is also very important
in the transportation of various molecules, including
bilirubin, free fatty acids, drugs, and hormones. Serum
albumin is an abundant multifunctional non-glycosy-
lated, negatively charged plasma protein, with ascribed
ligand-binding and transport properties, antioxidant
functions, and enzymatic activities [27].
A low serum albumin concentration indicates poor
liver function. Decreased serum albumin levels are not
seen in acute liver failure because it takes several weeks
of impaired albumin production until the serum albu-
min level drops. The most common reason for a low
albumin is chronic liver failure caused by cirrhosis. The
serum albumin concentration is usually normal in
chronic liver disease, until cirrhosis and significant liver
damage develops. In advanced liver disease, the serum
albumin level may be less than 3.5 g/dl. The albumin
level is clinically important as a predictive factor for
patients with liver cirrhosis, because decreased serum
albumin levels cause ascites and edema.
Recent studies have demonstrated the efficacy of
branched-chain amino acid (BCAA) supplementation
in improving hypoalbuminemia in cirrhotic patients
[28]. Kotho et al. investigated the correlation between
albumin levels and the fat-free mass in cirrhotic
patients [29]. They showed that exercise and protein-
rich nutrition at the early stage of liver cirrhosis may
be advisable for maintaining or increasing muscular
volume. Nishiguchi et al reported that if cirrhotic
patients were in the compensated stage at the entry
but with lower BCAA tyrosine ratio (BTR), oral BCAA
supplementation might be effective in maintaining
serum albumin [30]. Stating appropriate nutritional
interventions, such as supplementation of BCAA, in
t h ee a r l ys t a g eo fc i r r h o s i sm a yi m p r o v ep r o g n o s i sa n d
maintain QOL. We also reported that the administra-
tion of BCAA supplement (Aminofeel
®) increases
serum albumin levels and serum zinc levels, and
improves sensitivity to different tastes [31-33].
Conclusions
In conclusion, we demonstrated that the serum albumin
level is an independent risk factor for mortality from all
causes and an important prognostic indicator in the
residents of X town. In particular, improvement of
hypoalbuminaemia as well as the eradication of HCV,
such as by interferon therapy, should be considered for
improvement of prognosis in this hyperendemic area of
HCV infection in Japan.
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